

## **Medical Policies and Clinical Utilization Management Guidelines update**

*This communication applies to the Medicare Advantage and Medicare-Medicaid Plan (MMP) programs for Anthem Blue Cross (Anthem).*

The *Medical Policies, Clinical Utilization Management (UM) Guidelines* and *Third-Party Criteria* below were developed and/or revised to support clinical coding edits. Note, several policies and guidelines were revised to provide clarification only and are not included. Existing precertification requirements have not changed.

Please share this notice with other members of your practice and office staff. To view a guideline, visit <https://www11.anthem.com/search.html>.

### **Updates**

Updates marked with an asterisk (\*) denote that the criteria may be perceived as more restrictive:

- **MED.00134** — Non-invasive Heart Failure and Arrhythmia Management and Monitoring System:
  - Revised Investigational and Not Medically Necessary indications
- **SURG.00156** — Implanted Artificial Iris Devices:
  - Revised Investigational and Not Medically Necessary indications
- **SURG.00157** — Minimally Invasive Treatment of the Posterior Nasal Nerve to Treat Rhinitis:
  - Revised Investigational and Not Medically Necessary indications
- **CG-DME-07** — Augmentative and Alternative Communication (AAC) Devices with Digitized or Synthesized Speech Output:
  - Revised Medically Necessary and Not Medically Necessary indications
- **GENE.00052** — Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling:
  - Revised Medically Necessary indications
- **SURG.00077** — Uterine Fibroid Ablation: Laparoscopic, Percutaneous or Transcervical Image Guided Techniques:
  - Expanded scope and revised Investigational and Not Medically Necessary indications
- **SURG.00112** — Implantation of Occipital, Supraorbital or Trigeminal Nerve Stimulation Devices (and Related Procedures):
  - Revised scope and Investigational and Not Medically Necessary indications
- **CG-REHAB-12** — Rehabilitative and Habilitative Services in the Home Setting: Physical Medicine/Physical Therapy, Occupational Therapy and Speech-Language Pathology:
  - A **new Clinical UM Guideline** was created from content contained in CG-REHAB-04, CG-REHAB-05 and CG-REHAB-06.
  - There are no changes to the guideline content.
  - Publish date is scheduled for December 8, 2020.

\* AIM Specialty Health is an independent company providing some utilization review services on behalf of Anthem Blue Cross.

---

Anthem Blue Cross is the trade name of Blue Cross of California. Anthem Blue Cross and Blue Cross of California Partnership Plan, Inc. are independent licensees of the Blue Cross Association. Anthem is a registered trademark of Anthem Insurance Companies, Inc.

Anthem Blue Cross Cal MediConnect Plan is a health plan that contracts with both Medicare and Medi-Cal to provide benefits of both programs to enrollees.

Anthem BC Health Insurance Company is the trade name of Anthem Insurance Companies, Inc. Anthem Blue Cross, Anthem Blue Cross Life and Health Insurance Company and Anthem BC Health Insurance Company are independent licensees of the Blue Cross Association.

**Medical Policies**

On August 13, 2020, the Medical Policy and Technology Assessment Committee (MPTAC) approved the following *Medical Policies* applicable to Anthem. These guidelines take effect December 28, 2020.

<b>Publish date</b>	<b>Medical Policy #</b>	<b>Medical Policy title</b>	<b>New or revised</b>
10/7/2020	*MED.00134	<i>Non-invasive Heart Failure and Arrhythmia Management and Monitoring System</i>	New
10/7/2020	*SURG.00156	<i>Implanted Artificial Iris Devices</i>	New
10/7/2020	*SURG.00157	<i>Minimally Invasive Treatment of the Posterior Nasal Nerve to Treat Rhinitis</i>	New
9/1/2020	*GENE.00052	<i>Whole Genome Sequencing, Whole Exome Sequencing, Gene Panels, and Molecular Profiling</i>	Revised
10/7/2020	*SURG.00077	<i>Uterine Fibroid Ablation: Laparoscopic, Percutaneous or Transcervical Image Guided Techniques</i>	Revised
10/1/2020	*SURG.00112	<i>Implantation of Occipital, Supraorbital or Trigeminal Nerve Stimulation Devices (and Related Procedures)</i>	Revised

**Clinical UM Guidelines**

On August 13, 2020, the MPTAC approved the following *Clinical UM Guidelines* applicable to Anthem. These guidelines were adopted by the medical operations committee for our members on September 24, 2020. These guidelines take effect December 28, 2020.

<b>Publish date</b>	<b>Clinical UM Guideline #</b>	<b>Clinical UM Guideline title</b>	<b>New or revised</b>
10/7/2020	*CG-DME-07	<b>Augmentative and Alternative Communication (AAC) Devices with Digitized or Synthesized Speech Output</b>	Revised
10/7/2020	CG-DME-25	<b>Seat Lift Mechanisms</b>	Revised
8/20/2020	CG-GENE-03	<b>BRAF Mutation Analysis</b>	Revised
8/20/2020	CG-SURG-83	<b>Bariatric Surgery and Other Treatments for Clinically Severe Obesity</b>	Revised